How do you come off a GLP-1 without regaining the weight?

Written and medically reviewed by Zahraa Sater, M.D., M.P.H.

Reviewed August 12, 2026 · Next review due August 12, 2027

Short answer

No trial has shown that any tapering method prevents regain after stopping semaglutide or tirzepatide. In the STEP 1 extension people regained two thirds of their weight loss within a year, and in SURMOUNT-4 82 percent of those who stopped regained more than a quarter of what they had lost. The realistic plan is to build maintenance behaviours first and stop deliberately, with monitoring.

This is the question the industry answers least honestly, so here is the state of the evidence. There is no published trial showing that a slow taper, a supplement, a specific diet or a bridging medication prevents weight regain after a GLP-1 is stopped. What exists is data on what happens when people stop, and it is consistent.

What the withdrawal data shows

In the STEP 1 trial extension, 327 participants who had lost 17.3 percent of their body weight over 68 weeks on semaglutide were followed for a further year off treatment. They regained 11.6 percentage points, finishing 5.6 percent below their starting weight, and their cardiometabolic improvements reverted towards baseline. In SURMOUNT-4, among the 308 participants switched from tirzepatide to placebo, 82 percent regained more than a quarter of the weight they had lost within a year, and blood pressure, waist circumference, non-HDL cholesterol and HbA1c worsened in proportion to how much came back.

What a deliberate stop actually involves

The work happens before the last injection, not after it. Four things need to be in place and running without the drug's help: a protein intake at 1.2 to 1.6 g/kg per day that you can hit on ordinary days, resistance training at least three times a week, a sleep pattern that is not producing extra appetite, and an eating structure that does not depend on being uninterested in food. If any of those is still theoretical, stopping is premature. Reducing the dose stepwise while those habits are tested is more sensible than stopping from a maintenance dose in one move, although this is clinical judgement rather than trial-proven.

What to monitor after you stop

Weigh weekly under the same conditions and set a threshold in advance, for example 3 to 4 percent above your lowest stable weight, at which you contact your clinician rather than wait. Recheck blood pressure, HbA1c and lipids at three to six months, because these move before the scale tells the whole story. Keep the measurements you took before you started, so you have something to compare against. Regain is easier to interrupt at 4 kg than at 14 kg.

Treat a stop as a planned trial with a review date, not a discharge. If weight and metabolic markers hold at six months, you have your answer. If they do not, restarting is not a failure, it is the same decision you would make if blood pressure rose after stopping an antihypertensive.

The clinical detail

STEP 1 extension: mean weight change minus 17.3 percent at week 68 on semaglutide, minus 5.6 percent at week 120 after one year off drug, representing regain of roughly two thirds of the loss, with most cardiometabolic gains reverting. SURMOUNT-4: of 308 participants randomised from tirzepatide to placebo for 52 weeks, 54 regained less than 25 percent of lost weight, 77 regained 25 to less than 50 percent, 103 regained 50 to less than 75 percent and 74 regained 75 percent or more; systolic blood pressure rose 6.8 to 10.4 mmHg and HbA1c 0.14 to 0.35 percentage points across increasing regain strata, while those regaining under 25 percent showed minimal reversal. No randomised comparison of tapering versus abrupt discontinuation has been published.

Written and medically reviewed by Zahraa Sater, M.D., M.P.H.

Reviewed August 12, 2026 · Next review due August 12, 2027

Sources

  1. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. PMID 35441470
  2. SURMOUNT-4: Weight Reversal Post Tirzepatide Withdrawal. American College of Cardiology. PMID 38078870
  3. Nutritional Priorities to Support GLP-1 Therapy for Obesity: a joint Advisory. American Journal of Clinical Nutrition
  4. 2026 ADA Standards of Care: Obesity and Weight Management recommendations. American Diabetes Association via Guideline Central

Was this answer helpful?

This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.